Meeting
2021 Gastrointestinal Cancers Symposium
Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.
Authors
Saikat Chowdhury
University of Texas MD Anderson Cancer Center, Houston, TX
Saikat Chowdhury , John Paul Y.C. Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 130)
DOI
10.1200/JCO.2021.39.3_suppl.130
Abstract #
130
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2023 ASCO Annual Meeting
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.
First Author: Sian Alexandra Pugh
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2021 ASCO Annual Meeting
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.
First Author: Giulia Martini